ArticleEye (London, England)2012
Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity.
Article in Eye (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Pooled it
- Dexamethasone Eye Drops to Prevent Treatment-Requiring Retinopathy of Prematurity: The DROPROP Randomized Clinical Trial.JAMA pediatrics · 2026Article
- Article
- Enhancing Late Retinopathy of Prematurity Outcomes with Fresh Bone Marrow Mononuclear Cells and Melatonin Combination Therapy.Stem cell reviews and reports · 2025Article
- Comparison of ranibizumab and conbercept treatment in type 1 prethreshold retinopathy of prematurity in zone II.BMC pediatrics · 2024Article
- Retinopathy of prematurity: a review of epidemiology and current treatment strategies.Clinical and experimental pediatrics · 2022Article
- Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.Current opinion in ophthalmology · 2021Review
- Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors.International journal of retina and vitreous · 2021Article
- Risk factors associated with avascular fibrous membrane in patients with retinopathy of prematurity.International ophthalmology · 2020Article
- Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.Korean journal of ophthalmology : KJO · 2018Article
- Vitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity: a case series.International journal of retina and vitreous · 2018Article
- Retinopathy of prematurity: preferred practice patterns among pediatric ophthalmologists.Clinical ophthalmology (Auckland, N.Z.) · 2018Article
- Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment.Journal of ophthalmology · 2017Article
- Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.Ophthalmology · 2016Article
- Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.Seminars in perinatology · 2016Review
- Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage.Journal of ophthalmology · 2016Article
- Screening and Treatment in Retinopathy of Prematurity.Deutsches Arzteblatt international · 2015Review
- Article
- Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser.Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report a series of patients who presented with an atypical retinal traction band, which was developed after an intravitreal injection of bevacizumab for stage 3 retinopathy of prematurity (ROP).
methodsWe retrospectively reviewed the medical record of three patients (five eyes) who had been referred to a tertiary care centre for the management of fibrous retinal traction band, which occurred after a bevacizumab injection for stage 3 ROP with plus disease. Clinical features and courses of these eyes were described based on the medical record and RetCam fundus photography.
resultsAll three patients had taken an intravitreal injection of bevacizumab with or without concomitant laser photocoagulation as an initial treatment option for the active stage 3 ROP. With close follow-ups, regression of extraretinal fibrovascular proliferation and plus disease was noted invariably. After the regression of ROP, atypical fibrous traction membrane had arisen along the major vascular arcades with 2.5 to 4 months of latency, which progressed into tractional retinal detachment (TRD) in three out of five eyes.
conclusionIn active stage 3 ROP, fibrous tractional membrane and subsequent TRD along the major vascular arcades were developed unpredictably after the regression of neovascular activity following bevacizumab injection as an initial treatment. Therefore, ROP patients who received bevacizumab treatment without previous retinal photocoagulation should be closely followed for more than 4 months after the treatments even if the disease seems to have regressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.